NEW DELHI--January 19, 2024--Researched by Industrial Info Resources (Sugar Land, Texas)--The human papillomavirus (HPV) vaccine, a preventive vaccine designed to protect against HPV infections and associated complications (like cervical cancer, anal cancer and genital warts), has received differing opinions and approaches from various regions around the world. While many countries have adopted the HPV vaccine as part of their national immunization programs, others have shown concerns about its potential side effects and long-term impacts.

Industrial Info is tracking 11 active capital-spending projects globally, worth US$612.31 million, aimed at the production of HPV vaccines.